Related Experiment Video
Updated: Aug 9, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.7K
Statin's role on blood pressure levels: Meta-analysis based on randomized controlled trials
Hui Ting Liu1, Nian Hua Deng1, Ze Fan Wu1
1Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, University of South China, Hengyang, Hunan, PR China.
Journal of Clinical Hypertension (Greenwich, Conn.)
|February 17, 2023
Summary
Statins may slightly lower blood pressure (BP), with a small but statistically significant reduction observed in systolic and diastolic BP. Further large-scale studies are needed to confirm these findings and their clinical significance.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Statins are primarily used to reduce cardiovascular events.
- Their potential role in blood pressure (BP) management and as antihypertensives remains debated.
- This study investigates the BP-lowering effects of statins.
Approach:
- A comprehensive meta-analysis was conducted, searching major databases (Scopus, PubMed, Web of Science, Cochrane) from 2002-2022.
- Included randomized controlled trials (RCTs) examining statin effects on BP in normotensive and hypertensive individuals.
- Analyzed changes in systolic and diastolic BP as primary outcomes.
Key Points:
- The meta-analysis included 49 RCTs with 45,173 participants.
- A statistically significant reduction in systolic BP (ΔSBP = -1.42 mmHg) and diastolic BP (ΔDBP = -0.82 mmHg) was observed.
- While significant, the magnitude of BP reduction was modest.
Conclusions:
- Statins demonstrated a statistically significant, albeit small, effect on lowering both systolic and diastolic blood pressure.
- The clinical significance of this modest BP reduction warrants further investigation.
- Larger, long-term, multi-center, and multi-ethnic studies are recommended to definitively establish statins' antihypertensive potential.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
728
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
728
01:25Antihypertensive Drugs: Direct Renin Inhibitors
726
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
726
01:26Atherosclerosis III: Management
16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
737
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
737
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
155
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
155
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
796
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
796